Australian M&A and equity raisings
1,881 deals since January 2025, each with its advisers and sources · as at 8 Nov 2026 · Venture rounds
116 deals · A$3.4bndisclosed · Health care · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value A$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Nov 2026 | Clever Culture Systems | – | – | Placement | Announced | 1.0 | Medical devices and technology | Blue Ocean Equities (lead manager)Taylor Collison (lead manager) |
| Nov 2026 | Neurizon Therapeutics | – | – | Placement | Announced | 4.3 | Biotech and pharmaceuticals | MST Financial (lead manager)Morgans (lead manager) |
| Oct 2026 | Resonance Health | – | – | Placement | Completed | 6.0 | Medical devices and technology | Bell Potter (lead manager) |
| Oct 2026 | Invex Therapeutics | – | – | Placement | Announced | 10.0 | Biotech and pharmaceuticals | CPS Capital Group (lead manager) |
| Oct 2026 | Identifai Genetics | – | – | IPO | Listed | 10.0 | Biotech and pharmaceuticals | Nova Legal (issuer)Gornitzky (issuer)Herzog Patents (Cohn, de Vries, Stadler & Co.) (issuer)RSM (issuer)Pendragon Capital (issuer)Aesir Corporate (lead manager) |
| Oct 2026 | Cynata Therapeutics | – | – | Entitlement offer | Completed | 0.9 | Biotech and pharmaceuticals | Caravel Securities (lead manager) |
| Sep 2026 | Nyrada | – | – | Placement | Completed | 14.0 | Biotech and pharmaceuticals | Bell Potter (lead manager) |
| Sep 2026 | CurveBeam AI | – | – | Share purchase plan | Completed | 1.8 | Medical devices and technology | Spark Plus (issuer) |
| Aug 2026 | Prescient Therapeutics | – | – | Share purchase plan | Completed | – | Biotech and pharmaceuticals | Reach Markets (lead manager) |
| Aug 2026 | TALi Digital | – | – | Placement | Completed | 3.3 | Medical devices and technology | Sixty Two Capital (lead manager) |
| Aug 2026 | Xenitra | – | – | Placement | Completed | 1.5 | Biotech and pharmaceuticals | Novus Capital (lead manager) |
| Jul 2026 | Radiopharm Theranostics | – | – | Placement | Completed | 12.5 | Biotech and pharmaceuticals | McCullough Robertson (issuer)Bell Potter (lead manager)H.C. Wainwright & Co. (lead manager) |
| Jul 2026 | Starpharma Holdings | – | – | Entitlement offer | Completed | 32.0 | Biotech and pharmaceuticals | DLA Piper (issuer)Canaccord Genuity (lead manager) |
| Jul 2026 | Imugene | – | – | Placement | Completed | 11.1 | Biotech and pharmaceuticals | Bell Potter (lead manager) |
| Jul 2026 | Enlitic | – | – | Placement | Completed | 15.0 | Medical devices and technology | Barrenjoey (lead manager) |
| Jul 2026 | Echo IQ | – | – | Placement | Completed | 110.0 | Medical devices and technology | Ord Minnett (lead manager)Morgans (lead manager) |
| Jun 2026 | Recce Pharmaceuticals | – | – | Placement | Completed | 4.0 | Biotech and pharmaceuticals | Ord Minnett (lead manager)Spark Plus (lead manager) |
| Jun 2026 | Control Bionics | – | – | Placement | Completed | 10.0 | Medical devices and technology | Bell Potter (lead manager)Unified Capital Partners (lead manager) |
| Jun 2026 | CONNEQT Health | – | – | Placement | Completed | 5.5 | Medical devices and technology | Stralis Capital Partners (lead manager) |
| Jun 2026 | Vitrafy Life Sciences | – | – | Placement | Completed | 30.0 | Medical devices and technology | Bell Potter (lead manager)Jarden (lead manager)Morgans (lead manager) |
| Jun 2026 | EBR Systems | – | – | Entitlement offer | Completed | 150.0 | Medical devices and technology | Johnson Winter Slattery (issuer)Canaccord Genuity (lead manager)E&P Capital (lead manager)Morgans (lead manager) |
| May 2026 | Tetratherix | – | – | Placement | Completed | 15.0 | Medical devices and technology | Barrenjoey (lead manager)Morgans (lead manager) |
| May 2026 | TruScreen Group | – | – | Entitlement offer | Completed | – | Medical devices and technology | Russell McVeagh (issuer)Addisons (issuer) |
| May 2026 | TruScreen Group | – | – | Placement | Announced | – | Medical devices and technology | Spark Plus (lead manager)Erity Capital (lead manager) |
| May 2026 | Hydrix | – | – | Entitlement offer | Completed | 8.2 | Medical devices and technology | Thomsons (issuer)Peak Asset Management (lead manager) |
| May 2026 | Pacific Edge | – | – | Placement | Completed | – | Medical devices and technology | Cameron Partners (issuer)Harmos Horton Lusk (issuer)The Project NZ (issuer) |
| May 2026 | InteliCare Holdings | – | – | Placement | Completed | 2.1 | Medical devices and technology | Westar Capital (lead manager)Candour Advisory (lead manager) |
| May 2026 | AdAlta | – | – | Placement | Completed | 2.5 | Biotech and pharmaceuticals | Sixty Two Capital (lead manager) |
| May 2026 | ImpediMed | – | – | Placement | Completed | 15.2 | Medical devices and technology | Clifford Chance (issuer)Bell Potter (lead manager)Canaccord Genuity (lead manager) |
| May 2026 | Imricor Medical Systems | – | – | Placement | Completed | 60.0 | Medical devices and technology | Morgans (lead manager)Canaccord Genuity (lead manager)Taylor Collison (lead manager) |
| Apr 2026 | Syntara | – | – | Placement | Completed | 8.0 | Biotech and pharmaceuticals | Canaccord Genuity (lead manager)Euroz Hartleys (lead manager) |
| Apr 2026 | Paradigm Biopharmaceuticals | – | – | Placement | Completed | 14.0 | Biotech and pharmaceuticals | Barrenjoey (lead manager)Bell Potter (lead manager) |
| Mar 2026 | 4DMedical | – | – | Placement | Completed | 83.0 | Medical devices and technology | Bell Potter (lead manager) |
| Mar 2026 | Lumos Diagnostics Holdings | – | – | Placement | Completed | 20.0 | Medical devices and technology | MST Financial (lead manager)Barrenjoey (lead manager)Foster Stockbroking (lead manager) |
| Mar 2026 | Oneview Healthcare | – | – | Placement | Completed | 19.0 | Medical devices and technology | MST Financial (lead manager) |
| Mar 2026 | Percheron Therapeutics | – | – | Entitlement offer | Announced | 2.2 | Biotech and pharmaceuticals | Hamilton Locke (issuer)Blue Ocean Equities (lead manager)Cygnet Capital (lead manager) |
| Mar 2026 | EVE Health Group | – | – | Placement | Completed | 1.3 | Biotech and pharmaceuticals | Red Leaf Securities (lead manager) |
| Mar 2026 | Imugene | – | – | Convertible | Announced | 20.0 | Biotech and pharmaceuticals | McCullough Robertson (issuer) |
| Feb 2026 | Botanix Pharmaceuticals | – | – | Placement | Completed | 40.0 | Biotech and pharmaceuticals | Euroz Hartleys (lead manager)Canaccord Genuity (lead manager) |
| Feb 2026 | Adherium | – | – | Entitlement offer | Completed | 7.5 | Medical devices and technology | Stralis Capital Partners (lead manager)PAC Partners (lead manager)TradeIdea (lead manager) |
| Feb 2026 | Cyclopharm | – | – | Placement | Completed | 14.0 | Medical devices and technology | Barrenjoey (lead manager)Bell Potter (lead manager) |
| Feb 2026 | Island Pharmaceuticals | – | – | Placement | Completed | 9.0 | Biotech and pharmaceuticals | ORA Capital (lead manager) |
| Feb 2026 | OncoSil Medical | – | – | Placement | Completed | 8.0 | Medical devices and technology | Bell Potter (lead manager) |
| Feb 2026 | Actinogen Medical | – | – | Placement | Completed | 17.0 | Biotech and pharmaceuticals | Canaccord Genuity (lead manager) |
| Feb 2026 | PYC Therapeutics | – | – | Entitlement offer | Completed | 653.0 | Biotech and pharmaceuticals | Herbert Smith Freehills Kramer (issuer)Bloom Burton & Co. (lead manager)E&P Capital (lead manager)Barrenjoey (lead manager) |
| Jan 2026 | BPH Energy | – | – | Placement | Completed | 1.2 | Biotech and pharmaceuticals | Sixty Two Capital (lead manager)Oakley Capital Partners (lead manager) |
| Dec 2025 | Chimeric Therapeutics | – | – | Placement | Completed | 4.4 | Biotech and pharmaceuticals | PAC Partners (lead manager)Taylor Collison (lead manager) |
| Dec 2025 | Chimeric Therapeutics | – | – | Placement | Completed | 8.4 | Biotech and pharmaceuticals | McCullough Robertson (issuer)PAC Partners (lead manager)Taylor Collison (lead manager) |
| Dec 2025 | Neurizon Therapeutics | – | – | Placement | Completed | 24.2 | Biotech and pharmaceuticals | Morgans (lead manager) |
| Dec 2025 | Cleo Diagnostics | – | – | Placement | Completed | 5.0 | Medical devices and technology | Petra Capital (lead manager) |
Deals come from ASX announcements, scheme booklets, prospectuses, the advisers' own deal announcements and the press. How the data is built